Corporate Member Update: Bristol Myers Squibb

Corporate Member Update: Bristol Myers Squibb

Opdivo® (nivolumab)
April, 2021

U.S. Food and Drug Administration Approves Opdivo® (nivolumab) in Combination with Chemotherapy for Patients with Advanced or Metastatic Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma, Regardless of PD-L1 Expression

To read more about the approval, please visit our official press release page.

 

 

 

 
 
Become a NOS Member Today!
 

Platinum Corporate Members

Gold Corporate Members